Infobox drug class

Infobox template for drug classes and medication classes

Purpose

Template:Infobox drug class is an infobox template for medication classes, drug mechanisms, and therapeutic drug groups such as GLP-1 receptor agonist, dual GIP and GLP-1 receptor agonist, anti-obesity medication, diabetes medication, and related pharmacologic classes.

Usage

Copy and paste the following code into an article and fill in the relevant fields.

{{Infobox drug class
| class = Dual GIP and GLP-1 receptor agonist
| image = [[File:Before-and-after-weight-loss.jpeg|250px]]
| caption = Dual GIP and GLP-1 receptor agonists act on two incretin pathways involved in insulin secretion, appetite, satiety, and body weight.
| type = Incretin-based therapy
| mechanisms = [[GIP receptor]] activation and [[GLP-1 receptor]] activation
| receptors = [[GIP receptor]], [[GLP-1 receptor]]
| fda_approved_example = [[Tirzepatide]]
| examples = [[Tirzepatide]]
| brand_examples = [[Mounjaro]], [[Zepbound]]
| investigational_examples = [[Retatrutide]], VK2735
| uses = [[Type 2 diabetes]], [[chronic weight management]], [[obesity]], [[overweight]]
| route = [[Subcutaneous injection]]
| frequency = Once weekly
| related_classes = [[GLP-1 receptor agonist]], [[GIP receptor agonist]], [[anti-obesity medication]], [[diabetes medication]]
| related = [[Tirzepatide weight loss]], [[Zepbound for weight loss]], [[Mounjaro for weight loss]], [[GLP-1 weight loss injections]]
}}

Parameters

Parameter	Description
class	Name of the drug class. If omitted, the page name is used.
name	Optional alternate name; overrides class if used.
image	Full file syntax, such as [[File:Semaglutide structure.svg|250px]].
caption	Caption below the image.
type	General class type, such as incretin-based therapy or anti-obesity medication.
mechanism or mechanisms	Main mechanism of action.
receptors	Target receptors, if applicable.
fda_approved_example	FDA-approved example medication.
examples	General medication examples.
brand_examples	Brand-name examples.
investigational_examples	Drugs currently under study.
uses	Common or approved uses.
route or routes	Route of administration.
frequency	Common dosing frequency.
related_classes	Related drug classes.
related	Related article links.

Example

Dual GIP and GLP-1 receptor agonist
Dual GIP and GLP-1 receptor agonists act on two incretin pathways involved in insulin secretion, appetite, satiety, and body weight.
Type	Incretin-based therapy
Mechanism	GIP receptor activation and GLP-1 receptor activation
Receptors	GIP receptor, GLP-1 receptor
FDA-approved example	Tirzepatide
Brand examples	Mounjaro, Zepbound
Investigational examples	Retatrutide, VK2735
Uses	Type 2 diabetes, chronic weight management, obesity, overweight
Route	Subcutaneous injection
Frequency	Once weekly
Related classes	GLP-1 receptor agonist, GIP receptor agonist, anti-obesity medication, diabetes medication
Related	Tirzepatide weight loss, Zepbound for weight loss, Mounjaro for weight loss, GLP-1 weight loss injections

TemplateData

<templatedata> {

 "description": "Infobox for medication classes, pharmacologic classes, drug mechanisms, and therapeutic drug groups.",
 "params": {
   "class": {
     "label": "Class",
     "description": "Name of the drug class.",
     "type": "string",
     "suggested": true
   },
   "name": {
     "label": "Name",
     "description": "Optional alternate display name. Overrides class if provided.",
     "type": "string"
   },
   "image": {
     "label": "Image",
     "description": "Full MediaWiki file syntax, such as .",
     "type": "wiki-file-name"
   },
   "caption": {
     "label": "Caption",
     "description": "Caption displayed under the image.",
     "type": "string"
   },
   "type": {
     "label": "Type",
     "description": "General category or type of drug class.",
     "type": "string"
   },
   "mechanisms": {
     "label": "Mechanisms",
     "description": "Main mechanism or mechanisms of action.",
     "type": "string"
   },
   "mechanism": {
     "label": "Mechanism",
     "description": "Alternate singular parameter for mechanism of action.",
     "type": "string"
   },
   "receptors": {
     "label": "Receptors",
     "description": "Target receptors, if applicable.",
     "type": "string"
   },
   "fda_approved_example": {
     "label": "FDA-approved example",
     "description": "FDA-approved drug example in this class.",
     "type": "string"
   },
   "examples": {
     "label": "Examples",
     "description": "Medication examples.",
     "type": "string"
   },
   "brand_examples": {
     "label": "Brand examples",
     "description": "Brand-name examples.",
     "type": "string"
   },
   "investigational_examples": {
     "label": "Investigational examples",
     "description": "Investigational or emerging medications.",
     "type": "string"
   },
   "uses": {
     "label": "Uses",
     "description": "Common or approved uses.",
     "type": "string"
   },
   "route": {
     "label": "Route",
     "description": "Route of administration.",
     "type": "string"
   },
   "routes": {
     "label": "Routes",
     "description": "Alternate plural parameter for route of administration.",
     "type": "string"
   },
   "frequency": {
     "label": "Frequency",
     "description": "Common dosing frequency.",
     "type": "string"
   },
   "related_classes": {
     "label": "Related classes",
     "description": "Related drug classes.",
     "type": "string"
   },
   "related": {
     "label": "Related",
     "description": "Related article links.",
     "type": "string"
   }
 },
 "format": "block"

} </templatedata>